相关实验视频

Updated: Jun 10, 2025

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

长期的乳腺癌对CDK4/6抑制的反应是由TP53-介导的转基因转换定义的

Rei Kudo¹, Anton Safonov², Catherine Jones³

¹Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSK), New York, NY 10065, USA; Department of Surgery, The Jikei University School of Medicine, Tokyo 1058461, Japan.

|October 11, 2024

概括

转移性激素受体阳性乳腺癌中TP53的丧失,通过促进细胞循环的重新进入,阻碍了对CDK4/6抑制剂的长期反应. 对CDK4/6和CDK2激酶的双抑制对于克服耐药性和实现持久的疾病控制至关重要.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症遗传学癌症遗传学

背景情况:

循环素依赖激酶 (CDK) 4/6 抑制剂改善了激素受体阳性 (HR+) 乳腺癌的结果.
然而,只有少数患者能够长期控制疾病,这表明了耐药性机制.

研究的目的:

在转移性HR+乳腺癌中识别与缺乏对CDK4/6抑制剂的长期反应相关的基因组变异.
在TP53损失的背景下,阐明基底抵抗CDK4/6抑制的分子机制.
评估克服CDK4/6抑制剂耐药性的治疗策略.

主要方法:

对大量转移性HR+乳腺癌患者的临床注释队列的分析.
利用人类乳腺癌模型研究TP53损失的功能后果.
评估了p53损失对细胞循环调节和药物反应的影响.
评估了CDK2抑制剂与CDK4/6抑制剂结合的疗效.

主要成果:

TP53损失 (27.6%) 和MDM2放大 (6.4%) 与缺乏长期疾病控制有关.
p53的损失没有影响CDK4/6活动或G1细胞循环停止,但促进了CDK2-介导的p130酸化.
持续的-p130抑制了DREAM复合体的组合,导致细胞循环的重新进入和瘤的进展.
抑制CDK2诱导了体质转化和衰老表型,克服了p53损失介导的抗性.

结论:

在HR+乳腺癌中,TP53损失是对CDK4/6抑制剂耐药性的关键机制.
需要对CDK4/6和CDK2激酶进行双重抑制,以克服由TP53损失驱动的抗性.
这种组合策略可能有助于基因组多样化HR+乳腺癌的长期反应.

关键词:

在CDK2中使用CDK2.在CDK4/6中使用.乳腺癌乳腺癌乳腺癌细胞循环中的细胞循环.循环林依赖性激酶是一种依赖性激酶.药物耐药性耐药性药物耐药性在 p53 里,p53 是一个 p53 号码.静止是一种静止.衰老是一种老化.

更多相关视频

In Vitro Evaluation of Oncogenic Transformation in Human Mammary Epithelial Cells

In Vitro Evaluation of Oncogenic Transformation in Human Mammary Epithelial Cells

Published on: September 24, 2020

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...